Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of IGEV with or without bortezomib before high-dose consolidation in relapsed or refractory Hodgkin lymphoma
2007-004883-29Phase 2Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Feb 2008
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib, ifosfamide, gemcitabine and vinorelbine in Hodgkin lymphoma (HL) (2 arms), sponsored by Humanitas Research Hospital. Started Feb 2008; status: completed.
02
Drugs
bortezomibifosfamidegemcitabinevinorelbine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2007-004883-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004883-29.